We are delighted to announce the appointment of Jacobus (Co) Bosch as CHDR’s Research Director Oncology as of 01 January 2022.
Co comes with a wealth of experience in translational (immuno-)oncology. He received his basic medical training at Leiden University Medical Center (LUMC), and obtained his MD and PhD from Leiden University. During this time, Co embarked on a journey to accomplish a pre-doctoral research fellowship in Ocular-Immunology at Schepens Eye Research Institute of Mass. Eye and Ear, Harvard Medical School and a post-doc in Tumour-Immunology at the Department of Biological Sciences, University of Maryland Baltimore County, prior to his residency and clinical fellowship combined with research group leadership in Internal Medicine, Hematology and Medical Oncology at the University Hospital Erlangen. Co joins CHDR from the Center for Clinical Trials of Hannover Medical School (MHH) in Germany, where he was the Senior Physician and Head of Clinical Operations clinically responsible for MHH’s Early Clinical Trial Unit within Hannover’s Clinical Research Center.
Koos Burggraaf, CEO CHDR: “We are very happy to welcome Co. The rapidly changing field of (immuno-)oncology and the increasing complexity of early phase clinical trials in this area call for an expert approach, and we are confident that Co brings the necessary expertise to successfully expand our activities in this area.”
Co Bosch: “I am thrilled to start this innovative role in oncology at CHDR. It was a privilege to work with so many incredible people at various inspiring places during my journey in basic and clinical (immuno-)oncology for the past 2 decades. With gratitude and a sense of home coming, I am very proud to join CHDR’s excellent interdisciplinary team and passionate to move CHDR Oncology forward together with our partners. Keep an eye on us by following our updates at www.chdr.nl and social media."
